Search
Aptevo Therapeutics Inc
APVOAdd to Watchlist
4.110USD
-0.020-0.48%
Close 07-31 16:00（ET）Quotes delayed by 15 min
4.10MMarket Cap
0.00P/E TTM
More Details of Aptevo Therapeutics Inc Company
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Aptevo Therapeutics Inc Info
Ticker SymbolAPVO
Company nameAptevo Therapeutics Inc
IPO dateJul 20, 2016
CEOWhite (Marvin L)
Number of employees37
Security typeOrdinary Share
Fiscal year-endJul 20
Address2401 4th Ave Ste 1050
CitySEATTLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code98121-3460
Phone12068380500
Websitehttps://aptevotherapeutics.com/
Ticker SymbolAPVO
IPO dateJul 20, 2016
CEOWhite (Marvin L)
Company Executives of Aptevo Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.00
+33.33%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
1.00
--
Mr. Daniel J. Abdun-Nabi, J.D.
Mr. Daniel J. Abdun-Nabi, J.D.
Independent Director
Independent Director
--
--
Mr. Grady Grant, III
Mr. Grady Grant, III
Independent Director
Independent Director
--
--
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
--
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
Ms. Daphne L. Taylor
Ms. Daphne L. Taylor
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.00
+33.33%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
1.00
--
Mr. Daniel J. Abdun-Nabi, J.D.
Mr. Daniel J. Abdun-Nabi, J.D.
Independent Director
Independent Director
--
--
Mr. Grady Grant, III
Mr. Grady Grant, III
Independent Director
Independent Director
--
--
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Aptevo Therapeutics Inc?
The top five shareholders of Aptevo Therapeutics Inc are: Mr. Marvin L. White
How many institutions hold shares of Aptevo Therapeutics Inc (APVO)?
As of 2026Q1, 38 institutions hold shares of Aptevo Therapeutics Inc, with a combined market value of approximately 55.65K, accounting for 4.71% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 16735.00.